- Exploratory phase 1b trial will evaluate safety, tolerability and effect on pain intensity - Topline data readout planned for early 2026 SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc.
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results